Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Advertisement
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in relapsed or refractory LBCL.
ADX-2191 is a sterile, noncompounded intravitreal formulation of methotrexate.
The FDA is expected to make a final decision on the supplemental BLA for polatuzumab vedotin-piiq in DLBCL in early April.
Dr. Pickl discusses potential future uses and implications of a novel biomarker to predict responses to CAR-T in DLBCL.
AB-101 is an allogeneic, cryopreserved, ADCC-enhancing natural killer-cell therapy.
Advertisement
Winfried F. Pickl, MD, discusses a novel biomarker that can predict CAR-T responses in patients with DLBCL.
The study's investigators identified a four-gene model that segregated patients with different survival probabilities.
Advocates hope it will bring much-needed changes to patient care for complex cancers—including hematologic malignancies.
The estimated 24-month nonrelapse mortality was significantly lower in the CAR-T cohort than in the allogeneic HSCT cohort.
The results showed pembrolizumab was well tolerated, with 23.5% of patients achieving a complete response.
Given the multitude of novel therapies recently approved, clinicians must consider how to best sequence the options.
CAR-T therapy leads to responses in most patients with aggressive B-cell lymphoma, but durable CRs only occur in a minority.
Glofitamab is an investigational CD20×CD3 T-cell-engaging bispecific antibody.
Michael Dickinson, MBBS, DMedSc, discusses trials in progress that are evaluating glofitamab with other agents for DLBCL.
Michael Dickinson, MBBS, DMedSc, discusses a phase II trial of glofitamab, a bispecific antibody, in patients with DLBCL.
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
Michael Dickinson, MBBS, DMedSc, discusses updates on glofitamab that were presented during the 2022 ASH meeting.
Survival outcomes are typically poor in patients with relapsed/refractory aggressive BCL who relapse after anti-CD19 CAR-T.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726